Compare · ABBV vs MNKD
ABBV vs MNKD
Side-by-side comparison of AbbVie Inc. (ABBV) and MannKind Corporation (MNKD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MNKD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 361.1x MNKD ($1.25B).
- Over the past year, ABBV is up 34.5% and MNKD is up 7.3% - ABBV leads by 27.1 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 8 for MNKD).
- ABBV has more recent analyst coverage (25 ratings vs 14 for MNKD).
- Company
- AbbVie Inc.
- MannKind Corporation
- Price
- $254.52+0.06%
- $4.03-0.49%
- Market cap
- $449.63B
- $1.25B
- 1M return
- +14.38%
- +4.01%
- 1Y return
- +34.48%
- +7.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2004
- News (4w)
- 23
- 8
- Recent ratings
- 25
- 14
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest MNKD
- Chief Financial Officer Prentiss Christopher B covered exercise/tax liability with 22,247 shares, decreasing direct ownership by 7% to 318,668 units (SEC Form 4)
- Pres, Endocrine Business Unit Marasco Dominic covered exercise/tax liability with 3,623 shares, decreasing direct ownership by 1% to 343,398 units (SEC Form 4)
- Chief People & Workpl Officer Tross Stuart A converted options into 93,790 shares and covered exercise/tax liability with 65,808 shares, increasing direct ownership by 3% to 1,058,142 units (SEC Form 4)
- Chief Executive Officer Castagna Michael converted options into 350,260 shares and covered exercise/tax liability with 363,200 shares, decreasing direct ownership by 0.53% to 2,433,779 units (SEC Form 4)
- EVP Technical Operations Singh Sanjay R converted options into 70,550 shares and covered exercise/tax liability with 46,795 shares, increasing direct ownership by 5% to 478,966 units (SEC Form 4)
- EVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 98,426 shares, sold $97,641 worth of shares (24,109 units at $4.05) and converted options into 93,790 shares, decreasing direct ownership by 3% to 797,554 units (SEC Form 4)
- Director Binder Steven B. sold $213,089 worth of shares (52,485 units at $4.06), converted options into 93,790 shares and covered exercise/tax liability with 24,395 shares, increasing direct ownership by 2% to 824,918 units (SEC Form 4)
- MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
- Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
- MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF